Jean‐Marie Michot

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

Philippe Armand, Margaret A. Shipp, Vincent Ribrag et al. · Journal of Clinical Oncology · 2016 · 667 citations · Full text

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

Antoîne Italiano, Jean‐Charles Soria, Maud Toulmonde et al. · The Lancet Oncology · 2018 · 597 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +8

Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors

Eléonora De Martin, Jean‐Marie Michot, Barbara Papouin et al. · Journal of Hepatology · 2018 · 515 citations

Cancer Immunosurveillance, Hepatology, Hepatocellular Carcinoma +15

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

Myriam Delaunay, J. Cadranel, Amélie Lusque et al. · European Respiratory Journal · 2017 · 416 citations · Full text

Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer

Audrey Simonaggio, Jean‐Marie Michot, Anne Laure Voisin et al. · JAMA Oncology · 2019 · 354 citations · Full text